[go: up one dir, main page]

PE20251709A1 - Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento - Google Patents

Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento

Info

Publication number
PE20251709A1
PE20251709A1 PE2025001026A PE2025001026A PE20251709A1 PE 20251709 A1 PE20251709 A1 PE 20251709A1 PE 2025001026 A PE2025001026 A PE 2025001026A PE 2025001026 A PE2025001026 A PE 2025001026A PE 20251709 A1 PE20251709 A1 PE 20251709A1
Authority
PE
Peru
Prior art keywords
halogen
cyano
compound
optionally substituted
ddr1
Prior art date
Application number
PE2025001026A
Other languages
English (en)
Inventor
Kosuke Hashimoto
Junshi Asada
Mei Suganomata
Yohei Honda
Yota Tsuzuki
Keiji Kosugi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of PE20251709A1 publication Critical patent/PE20251709A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un compuesto que tiene actividad inhibidora de DDR1, de formula general (I), o una sal farmaceuticamente aceptable del mismo, o un solvato del mismo, y el uso farmaceutico del mismo. En particular, se refiere a un compuesto de la formula (I) caracterizado porque A es (a) en donde Y1, Y2, Y3 e Y4 son cada uno independientemente N o C-R5, en donde como maximo dos de Y1, Y2, Y3 e Y4 son N, y los otros son C-R5, R5 es H, halogeno, ciano, entre otros, y las lineas discontinuas son puntos de union; o (b) en donde R6a, R6b, R6c, R6d, R6e, R6f, R6g y R6h son cada uno independientemente H, halogeno, ciano o alquilo C1-C6 opcionalmente sustituido, y las lineas discontinuas son puntos de union; B es un anillo heterociclico monociclico de 3 a 8 miembros, saturado o insaturado, que contiene N, opcionalmente sustituido; X es N o C-R7, en donde R7 es H, halogeno, ciano o alquilo C1-C6 opcionalmente sustituido; los R1 se seleccionan cada uno independientemente de H, halogeno, ciano, entre otros; R2 y R3 son cada uno independientemente H, halogeno o alquilo C1-C6 opcionalmente sustituido; R4 es H, halogeno, ciano, entre otros; m es un numero entero de 0 a 3; n es un numero entero de 0 a 3; y Het es un anillo heterociclico saturado monociclico o biciclico de 5 a 10 miembros o un anillo heterociclico insaturado monociclico o biciclico de 5 a 10 miembros, o una sal farmaceuticamente aceptable del mismo, o un solvato del mismo.
PE2025001026A 2022-11-21 2023-11-20 Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento PE20251709A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022185827 2022-11-21
PCT/JP2023/041679 WO2024111560A1 (ja) 2022-11-21 2023-11-20 Ｄｄｒ１キナーゼ阻害剤としての化合物および医薬

Publications (1)

Publication Number Publication Date
PE20251709A1 true PE20251709A1 (es) 2025-07-02

Family

ID=91195603

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025001026A PE20251709A1 (es) 2022-11-21 2023-11-20 Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento

Country Status (12)

Country Link
EP (1) EP4624465A1 (es)
JP (1) JPWO2024111560A1 (es)
KR (1) KR20250109234A (es)
CN (1) CN120569374A (es)
AU (1) AU2023386923A1 (es)
CL (1) CL2025001435A1 (es)
CO (1) CO2025006877A2 (es)
IL (1) IL320735A (es)
MX (1) MX2025005556A (es)
PE (1) PE20251709A1 (es)
TW (1) TW202430151A (es)
WO (1) WO2024111560A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017A (en) 1841-03-26 The graphic co
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US9617242B2 (en) 2012-12-19 2017-04-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
CN108276388B (zh) * 2017-03-10 2020-01-14 成都医学院 1h-吲哚类衍生物及其用途
KR102297587B1 (ko) * 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7401856B2 (ja) 2018-12-21 2023-12-20 日産化学株式会社 高分子及び金属微粒子を含む無電解めっき下地剤
WO2020210642A1 (en) * 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use

Also Published As

Publication number Publication date
CN120569374A (zh) 2025-08-29
CL2025001435A1 (es) 2025-08-22
JPWO2024111560A1 (es) 2024-05-30
AU2023386923A1 (en) 2025-05-15
EP4624465A1 (en) 2025-10-01
IL320735A (en) 2025-07-01
CO2025006877A2 (es) 2025-06-06
MX2025005556A (es) 2025-06-02
TW202430151A (zh) 2024-08-01
KR20250109234A (ko) 2025-07-16
WO2024111560A1 (ja) 2024-05-30

Similar Documents

Publication Publication Date Title
AR127309A2 (es) Derivados de piridazinona
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR110753A1 (es) Inhibidores selectivos de jak1
PE20241625A1 (es) Combinaciones farmaceuticas de inhibidores de sos1 para tratar o prevenir cancer
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
PE20161031A1 (es) Agentes citotoxicos bifuncionales
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR116315A1 (es) Compuestos de triazolo-pirimidina y usos de los mismos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
MX2017015741A (es) Moduladores de ror gamma (ror?).
DOP2012000053A (es) Derivados de (tio) morfolina como moduladores de s1p
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
MX2024007312A (es) Inhibidor doble de pde3/4 heterociclico condensado triciclico y uso de este.
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
CO2023015244A2 (es) Inhibidores heteroaromáticos bicíclicos de la klk5
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
PE20230235A1 (es) Compuestos para modular la actividad de fxr y usos de los mismos
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco